WebMay 20, 2014 · FG-3019 is a CTGF-specific monoclonal antibody that decreases tumor growth and metastases and prolongs survival in the KPC mouse model of pancreatic … WebMay 26, 2006 · Thus, CTGF may be an attractive therapeutic target in a disease where monotherapy is unlikely to be successful, especially in those subsets of patients whose pancreatic cancers express high levels of CTGF. FG-3019, by blocking CTGF actions, may therefore represent a novel therapeutic option in PDAC and may ultimately have a …
CTGF antagonism with mAb FG-3019 enhances chemotherapy …
WebFG-3019 is an investigational therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders … WebOct 24, 2013 · Reagents CTGF monoclonal antibody. FG-3019 is a human IgG 1κ monoclonal antibody recognizing domain 2 of human and rodent CTGF, provided by FibroGen (San Francisco, CA). In the indicated experiments, whole molecular human IgG, purified from serum (Jackson ImmunoResearch), was used as the control. loadtronic 3 installation guide
Anti-Human CTGF Recombinant Antibody (FG-3019)
WebAs CTGF is a secreted protein, monoclonal antibodies are an option as blockade agents. The most advanced trials are of treatment with FG-3019/ pamrevlumab, a humanized anti-CTGF antibody, which has been tested in the clinic for muscular dystrophy, pancreatic cancer, liver fibrosis, idiopathic pulmonary fibrosis, and type 1 and 2 diabetes [3]. WebFG-3019 is a fully human monoclonal antibody that interferes with the action of connective tissue growth factor, a central mediator in the pathogenesis of fibrosis. This open-label phase 2 trial evaluated the safety and efficacy of two doses of FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks in patients with idiopathic pulmonary … WebPurpose: Connective tissue growth factor (CTGF) is overexpressed in pancreatic ductal adenocarcinoma (PDAC) and facilitates local desmoplasia, tumor progression and metastasis in animal models. This study evaluated safety and initial efficacy of the anti-CTGF antibody FG-3019 in combination with gemcitabine and erlotinib in indiana hs boys basketball tournament